Abstract
Abstract
Purpose
Circadian rhythm disruptors (e.g., night-shift work) are risk factors for breast cancer, however studies on their association with prognosis is limited. A small but growing body of research suggests that altered sleep patterns and eating behaviours are potential mechanistic links between circadian rhythm disruptors and breast cancer. We therefore systematically summarised literature examining the influence of circadian rhythm disrupting behaviours on cancer outcomes in women with breast cancer.
Methods
A systematic search of five databases from inception to January 2021 was conducted. Original research published in English, assessing the relationship between post-diagnosis sleep patters and eating behaviours, and breast cancer outcomes were considered. Risk of bias was assessed using the Newcastle–Ottawa Assessment Scale for Cohort Studies.
Results
Eight studies published original evidence addressing sleep duration and/or quality (k = 7) and, eating time and frequency (k = 1). Longer sleep duration (≥ 9 h versus [referent range] 6-8 h) was consistently associated with increased risk of all outcomes of interest (HR range: 1.37–2.33). There was limited evidence to suggest that measures of better sleep quality are associated with lower risk of all-cause mortality (HR range: 0.29-0.97). Shorter nightly fasting duration (< 13 h versus ≥ 13 h) was associated with higher risk of all breast cancer outcomes (HR range: 1.21–1.36).
Conclusion
Our review suggests that circadian rhythm disrupting behaviours may influence cancer outcomes in women with breast cancer. While causality remains unclear, to further understand these associations future research directions have been identified. Additional well-designed studies, examining other exposures (e.g., light exposure, temporal eating patterns), biomarkers, and patient-reported outcomes, in diverse populations (e.g., breast cancer subtype-specific, socio-demographic diversity) are warranted.
Funder
The University of Queensland
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J for Clinic 71(3):209–49. https://doi.org/10.3322/caac.21660
2. World Cancer Research Fund International/American Institute for Cancer Research. Continuous update project report: Diet, nutrition, physical activity, and breast cancer survivors 2014 https://www.wcrf.org/wp-content/uploads/2021/03/Breast-Cancer-Survivors-2014-Report.pdf. Accessed 13 Nov 2021
3. Levi F, Bosetti C, Lucchini F, Negri E, La Vecchia C (2005) Monitoring the decrease in breast cancer mortality in europe. Eur J Cancer Prev 14(6):497–502. https://doi.org/10.1097/00008469-200512000-00002
4. Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121(10):3786–3788. https://doi.org/10.1172/jci60534
5. Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S et al (2006) Metastatic breast cancer: An updating. Biomed Pharmacother 60(9):548–556. https://doi.org/10.1016/j.biopha.2006.07.086
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献